NDA 216984 · Shorla
Tepylute
Thiotepa · Intravenous
DiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jun 25, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
324
39 Phase 3, 55 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- TEPYLUTE · THIOTEPA 15MG/1.5ML (10MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- TEPYLUTE · THIOTEPA 100MG/10ML (10MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Thiotepa" as an intervention, any sponsor and status, largest first.
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01949129 · 1,800 participants (planned) · Start Apr 2013 · Primary completion Jun 1, 2030
Drug: VP16; Thiotepa and 6 more · For: Acute Lymphoblastic Leukaemia
Sites: Buenos Aires, Argentina; La Plata, Argentina; Melbourne, Australia · 119 sites in all
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Pivotal-lookingRecruiting
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT04221035 · 800 participants (planned) · Start Nov 5, 2019 · Primary completion Nov 2026
Drug: Vincristine; Carboplatin and 13 more · For: High-Risk Neuroblastoma; Patient With Insufficient Response Chemoimmunotherapy
Sites: Sydney, Australia; Clayton, Australia; Nedlands, Australia · 142 sites in all
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03126916 · 750 participants (planned) · Start May 14, 2018 · Primary completion Sep 30, 2030
Drug: Busulfan; Carboplatin and 13 more · For: Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 164 sites in all
- Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk NeuroblastomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00567567 · 665 participants · Start Nov 5, 2007 · Primary completion Feb 27, 2015
Drug: Carboplatin; Cisplatin and 9 more · For: Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 190 sites in all
- S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast CancerPivotal-lookingTerminated
SWOG Cancer Research NetworkResearch network
NCT00002772 · 602 participants · Start Jul 1996 · Primary completion Feb 2004
Drug: filgrastim; carboplatin and 7 more · For: Breast Cancer
Sites: New York, New York
- Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast CancerPivotal-lookingCompleted
Scottish Cancer Therapy NetworkAcademic, hospital or other
NCT00002755 · 600 participants (planned) · Start Nov 1995
Drug: filgrastim; CMF regimen and 6 more · For: Breast Cancer
Sites: Dublin, Ireland; Cambridge, United Kingdom; Cheltenham, United Kingdom · 21 sites in all
- Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast CancerPivotal-lookingCompleted
Pierre Fabre MedicamentIndustry
NCT01091168 · 594 participants · Start Jul 2009 · Primary completion Aug 27, 2012
Drug: vinflunine; Alkylating agent of physician choice registered in cancer · For: Breast Cancer; Metastases
Sites: Buenos Aires, Argentina; Quilmes, Argentina; Rosario, Argentina · 80 sites in all
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
NCT00303810 · 567 participants · Start Jan 2001 · Primary completion Dec 2013
Drug: carboplatin; cisplatin and 7 more · For: Brain and Central Nervous System Tumors
Sites: Hamburg, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, et al. · Lancet Haematol 2016 · Clinical Trial, Phase II, Multicenter Study
- Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
Sylvester RJ, Oosterlinck W, Holmang S, et al. · Eur Urol 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM, Cwynarski K, Pulczynski E, et al. · Leukemia 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Peters C, Dalle JH, Locatelli F, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Multicenter Study
- Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321).
Dunkel IJ, Piao J, Chantada GL, et al. · J Clin Oncol 2022 · Clinical Trial, Research Support, N.I.H., Extramural
- R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A, Correa DD, DeAngelis LM, et al. · Blood 2015 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
Sponsor: Shorla
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.